Daniel Lipinski, MSc, DPhil
Assistant Professor of Ophthalmology and Visual Sciences, Assistant Professor of Cell Biology, Neurobiology and Anatomy
Locations
- Medical College of Wisconsin Eye Institute
- 925 N. 87th St. Room Room 722
Milwaukee WI, 53226
Contact Information
Biography
Education
BSc, Biology, Imperial College London, UK
MSc, Virology, Imperial College London, UK
DPhil, Ophthalmology, University of Oxford, UK
Research Interests
Ocular Gene Therapy Lab
Research Interests
- Recombinant adeno-associated virus (rAAV)-mediated gene therapy
- Diabetic retinopathy
- Inherited retinal disease (e.g., Retinitis pigmentosa)
- Age-related macular degeneration (AMD)
Research Team
- Kristina J. Ertel, Graduate Student
- Dwani D. Patel, Graduate Student
- Hanmeng Zhang, Graduate Student
- Emily Nettesheim, Research Technologist
- Amira Pavlovich, Research Associate
Research Summary
The overarching theme of my research program is the development of broadly applicable gene-based therapeutics to preserve vision in neurodegenerative and vascular diseases affecting the retina. Toward this end, the Lipinski research group focuses on a number of key areas:
1) The development of recombinant adeno-associated virus (rAAV)-mediated gene therapies to prevent cone photoreceptor degeneration in end-stage retinitis pigmentosa.
2) Developing gene therapy approaches to target the retinal and choroidal vasculature in diabetic retinopathy and age-related macular degeneration.
3) Restoration of light sensitivity/vision in the totally degenerate retina.
Funding for this research: Department of Ophthalmology Special Endowment (PI: Lipinski DM)
Past grant support/funding: Juvenile Diabetes Research Foundation (JDRF) Innovative Grant (2014-2015, PI: Lipinski DM); Fulbright-Fight for Sight (UK) Research Scholarship (2013-2015, PI: Lipinski DM); Fight for Sight (UK) PhD Studentship (2009-2012, PI: MacLaren RE)
Publications
-
Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
(Yu FPS, Sajdak BS, Sikora J, Salmon AE, Nagree MS, Gurka J, Kassem IS, Lipinski DM, Carroll J, Medin JA.) Am J Pathol. 2019 Feb;189(2):320-338.
-
(Datta S, Renwick M, Chau VQ, Zhang F, Nettesheim ER, Lipinski DM, Hulleman JD.) Invest Ophthalmol Vis Sci. 2018 Oct 01;59(12):4909-4920.
-
Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD.
(Reid CA, Nettesheim ER, Connor TB, Lipinski DM.) Sci Rep. 2018 Aug 06;8(1):11763.
-
(Reid CA, Lipinski DM.) Methods Mol Biol. 2018;1715:19-31.
-
(Reid CA, Ertel KJ, Lipinski DM.) Invest Ophthalmol Vis Sci. 2017 12 01;58(14):6429-6439.
-
(Reid CA, Boye SL, Hauswirth WW, Lipinski DM.) Gene Ther. 2017 08;24(8):462-469.
-
(De Silva SR, Charbel Issa P, Singh MS, Lipinski DM, Barnea-Cramer AO, Walker NJ, Barnard AR, Hankins MW, MacLaren RE.) Gene Ther. 2016 11;23(11):767-774.
-
Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection.
(Lipinski DM, Reid CA, Boye SL, Peterson JJ, Qi X, Boye SE, Boulton ME, Hauswirth WW.) Hum Gene Ther. 2015 Nov;26(11):767-76.
-
CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa.
(Lipinski DM, Barnard AR, Singh MS, Martin C, Lee EJ, Davies WIL, MacLaren RE.) Mol Ther. 2015 Aug;23(8):1308-1319.
-
(Lipinski DM, Barnard AR, Charbel Issa P, Singh MS, De Silva SR, Trabalza A, Eleftheriadou I, Ellison SM, Mazarakis ND, MacLaren RE.) Hum Gene Ther. 2014 Jan;25(1):50-62.
-
(Tolmachova T, Tolmachov OE, Barnard AR, de Silva SR, Lipinski DM, Walker NJ, Maclaren RE, Seabra MC.) J Mol Med (Berl). 2013 Jul;91(7):825-37.
-
(Charbel Issa P, De Silva SR, Lipinski DM, Singh MS, Mouravlev A, You Q, Barnard AR, Hankins MW, During MJ, Maclaren RE.) PLoS One. 2013;8(4):e60361.
Ocular Gene Therapy
